Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term monitoring of DAA resistance persistence and SVR durability in chronic hepatitis C
2009-016560-36Phase 2Terminated
- Sponsor
- Roche
- Start
- Jun 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mericitabine, peginterferon alfa-2a and ribavirin in hepatitis C virus infection (2 cohorts), sponsored by Roche. Primary endpoints: Persistence of DAA-associated resistance mutations and Durability of SVR-24. Started Jun 2010; status: terminated.
02
Drugs
mericitabinepeginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-016560-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016560-36.